Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab versus placebo for coronary atherosclerosis after acute myocardial infarction
2024-520364-34-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and coronary arteriosclerosis comparing Ziltivekimab with Placebo (2 arms). Primary endpoint: Change in percent atheroma volume. Planned start Feb 2026; status: authorised.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2024-520364-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520364-34-00.